Member Info for Richob

.... from a number of broker platforms this week.

Anybody asking for 10000 shares and getting 500 now has @£9k due back and may have to wait until a week on Monday.

With all the talk of algorithms we get on here you would have thought a day would have been plenty of time.

I hope they are reading this and realise the potential problems they might well cause.

Rant over.

Onwards Avacta Group.

Hope you got the right Angle, DG, or they might think you are being obtuse.

I'm not fixated on ABDX, just don't see the point in paying out when you can own and according to the RNS:

"The Acquisition is the first step in a M&A-led growth strategy by Avacta for its diagnostics division, with the vision of building an integrated and differentiated IVD business with global reach serving professionals and consumers."

Integrated and differentiated are key words I think. M and A is self explanatory.

Followed by:

"The Company believes that there is a significant commercial opportunity in the EU and the UK markets, which are fragmented, to build its position in the immunodiagnostics and molecular diagnostics value chain by acquiring companies that are complementary to Avacta's core strengths in research and development."

A European manufacturer or two could also fit the bill and an Asian one or two as well. I think we have a link via Affyxell to a CDMC in Asia.

Just speculation based on the RNS.

All the best.

Onwards Avacta Group.

rxdav,

So you would rather pay someone to manufacture products you have developed rather than be in control of that part of the value chain?

Onwards Avacta Group.

... a fair amount of "rubbish" posted today.

One poster, Timster, I believe, has posted the only relevant point about the AVA6000 trial.

In addition to the above, which relates to the Therapeutics part of the business, we now have:

1) A Diagnostics business that already covers diagnostic distribution with cash flow.
2) A fair amount of cash in the bank to expand this (value chain and global reach).
3) Continued collaborations with some fairly large pharmas that clearly like and pay for their requirements.
4) A fair few "left field" opportunities, such as Affyxell and Point.
5) Pipelines of future products.

For my sins, like Wyndrum, I don't think we should get carried away just yet but for heaven's sake, could you ask much more?

Probably not but the company could have taken over seven times what it wanted from the open offer and didn't. The company clearly believes it has sufficient funds to achieve both Therapeutic and Diagnostic goals in both the near and long term.

Happy to hear otherwise.

Onwards Avacta Group.

You can't be called Energyshares and ask if the gas has gone out. LOL.

All the best.

Could it have been that "unknown" bloke that keeps cropping up, Wyndrum?

I'm with you on this one.

Onwards Avacta Group.

Agreed, VS.

It isn't me saying we shouldn't spend spare cash. Just replying to that.

Thanks.

Morning, Mr A. Just found your post from yesterday amidst all the codswallop about the share offer. You asked:

How many of those products sold by launch Diagnostics are Avacta's Richob?

None and neither are they Launch products. Launch, now Avacta, is a distributor. Launch clearly advertise these products for a reason and now it is Avacta advertising them.

How many of the manufacturers would instead have their goods manufactured in an Avacta-owned facility?

If you think the manufacturers are the developers of the products then none. Don't see how they are as Launch, now Avacta, offer manufacturing capability.

Or do you think Avacta would buy one of the manufacturers and their products?

I don't think manufacturers currently have their own products in that sense, so no.

Where do Affimers fit in all this?

Affimers fit in as future products.

I don't think Avacta are in any position to splash out spare cash. Not when the emphasis has been on diagnostics using Affimers.

The RNS is very clear about bringing about a Diagnostics Division with "global reach" that covers the "value chain".

As far as I see it, the value chain would include research and development, manufacturing, sales and distribution.

We clearly have research and development covered plus, it would seem, distribution across the UK and Europe. Our research and development is based on affimers.

Anyway, it is only a speculation on my part, so back to debating the share allocation I guess.

All the best.

Onwards Avacta Group.

4012 products according to the Launch Diagnostics website, Mr A.

Onwards Avacta Group.

Madness?

I thought the RNS said:

The Acquisition is the first step in a M&A-led growth strategy by Avacta for its diagnostics division, with the vision of building an integrated and differentiated IVD business with global reach serving professionals and consumers. The Company believes that there is a significant commercial opportunity in the EU and the UK markets, which are fragmented, to build its position in the immunodiagnostics and molecular diagnostics value chain by acquiring companies that are complementary to Avacta's core strengths in research and development.

I must have misunderstood the first sentence.

Apologies. Please go back to personal arguments instead.

Onwards Avacta Group.

Why is that, Hanoi?

Still think we will buy a manufacturer.

Both ABDX and ODX look affordable.

Onwards Avacta Group.

Fair call, icecool.

Onwards Avacta Group.

Over (for another poster).

Fair call, Mr A.

Just think that £7m for a UK manufacturer for a growing diagnostics division could be a steal but happy that we are on this topic.

Onwards Avacta Group.

Abingdon Health looks quite cheap currently.

Onwards Avacta Group.

Not a weekend of this, please.

Mr A has explained it enough times, surely?

I would rather we speculated o the next purchase for The Diagnostics Division.

I'll start with a manufacturer.

Onwards Avacta Group.

Thanks, Mr A.

It was the approach I was looking at and just wondered if it might be linked to Avacta but apparently it isn't, although disclosures does add Avacta to Bachovin at the end of your link, not that I am reading anything into this now.

Onwards Avacta Group.

Ok. Thanks.

Clinical trials must all follow a similar pattern I guess.

Onwards Avacta Group.

This looks very much like the approach taken with AVA6000 (obviously not as far on) and could be part of our link with Point:

https://www.pointbiopharma.com/our-products/pipeline/solid-tumors

Onwards Avacta Group.